Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer

Inclusion Criteria

• •1. Age ≥ 18 years at entry into the study.
• •2. Patient treated for hormone-dependent localized breast cancer requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
• •3. Patients treated with tamoxifen for a maximum of 1 to 3 years.
• •4. Patient affiliated with a Social Security system in France.
• •5. Patients who signed informed consent prior to inclusion in the study and prior to any specific study procedures.